Finland· FI-REL-REL56081

Rukobia

A fostemsavir product containing fostemsavir tromethamine, registered in Finland by ViiV Healthcare BV. The same ATC class is registered in 14 of our 19 countries.

ATC J05AX29

Checked against Fimea (Finland) on

Informational only — not a medical device.

SOURCE REGISTER · FIFimea (Finland)normalisedRukobiaATCJ05AX29REGISTER NO.FI-REL-REL56081PACKS LISTED1CHECKEDSeptember 27, 2026

Where it is registered

Fostemsavir is registered in 14 of 19 countries.

Countries holding a registration under ATC J05AX29 (fostemsavir), each read from that country’s own register.

  • This record: Finland, from Fimea (Finland)
  • 9 of them publish a price we can compare per daily dose

Fostemsavir · ATC J05AX29

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Fimea (Finland)
Active substance
Fostemsavir tromethamine
Manufacturer
ViiV Healthcare BV
Country
Finland (FI)
ATC code
J05AX29
ATC class
Fostemsavir
Defined daily dose
1.2 g, O
Reimbursed
Not published by this register
Source register
Fimea (Finland)
Last checked
September 27, 2026

Packs & prices · 1

1 priced
  • fi_myyntilupa
    036262
    60
    EUR 3585.6

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

232 interactions on record for fostemsavir.

Graded by severity as the source publishes them — 42 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Fostemsavir · interactions on record

232 records

  • 42 severe
  • 168 moderate
  • 22 minor

Most severe, free to view

  • PapaverineA03AD01severe
  • CisaprideA03FA02severe
  • DolasetronA04AA04severe
  • PapaverinC04AX38severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Fostemsavir in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All fostemsavir products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Rukobia
  • Liechtenstein · Rukobia
  • Norway · Rukobia

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/1fbcd18f-ed10-48a6-8c94-6887efe73004
GET /v1/drugs/1fbcd18f-ed10-48a6-8c94-6887efe73004?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "ddd": "1.2",
  "form": "depottabletti",
  "route": "Suun kautta",
  "ddd_unit": "g",
  "strength": "600 mg",
  "atc_label": "fostemsaviiri",
  "ma_number": null,
  "auth_status": "Myyntilupa myönnetty",
  "eu_ma_number": "EU/1/20/1518/001-002",
  "fimea_rel_id": "REL56081",
  "authorised_at": "2021-02-04"
}

See everything about fostemsavir.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.